Merger: absorbed by MULTIPHARMA
Dissolution of the company · Dissolved without liquidation · MULTIPHARMA holds all the shares · General meeting of 13-06-2024 · Gazette deed
Merger proposal: to be absorbed by MULTIPHARMA
Gazette deed
Name hiddenVisible after signing in reappointed as statutory auditorHidden nameVisible after signing in acts as permanent representative · General meeting of 08-06-2023 · Gazette deed
Name after signing inVisible after signing in resigns as directorName hiddenVisible after signing in appointed as director · General meeting of 03-12-2020 · Gazette deed
Absorbed by MULTIPHARMAmerger by absorption, April 2024
Activity
“A) Het verlenen van adviezen van financiële, technische, commerciële of administratieve aard, in de…” (deed in French)From the articles, 9 activitiesNo NACE code in the KBO
The turnover in financial year 2023 is about €230,000. This figure is estimated from the gross margin of €78,869 and 992 comparable companies of the same size. It probably lies between €140,000 and €460,000. It is a rough estimate.Financials
Is ARJURO profitable?
In financial year 2023, ARJURO made a profit of €49,927.
Where can I find the annual accounts of ARJURO?
ARJURO filed 20 annual accounts with the National Bank of Belgium, the latest for financial year 2023.